These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 28197314)

  • 1. Combretastatin A4-β-Galactosyl Conjugates for Ovarian Cancer Prodrug Monotherapy.
    Doura T; Takahashi K; Ogra Y; Suzuki N
    ACS Med Chem Lett; 2017 Feb; 8(2):211-214. PubMed ID: 28197314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development Of Novel Liposome-Encapsulated Combretastatin A4 Acylated Derivatives: Prodrug Approach For Improving Antitumor Efficacy.
    Gu Y; Ma J; Fu Z; Xu Y; Gao B; Yao J; Xu W; Chu K; Chen J
    Int J Nanomedicine; 2019; 14():8805-8818. PubMed ID: 31806973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative preclinical pharmacokinetic and metabolic studies of the combretastatin prodrugs combretastatin A4 phosphate and A1 phosphate.
    Kirwan IG; Loadman PM; Swaine DJ; Anthoney DA; Pettit GR; Lippert JW; Shnyder SD; Cooper PA; Bibby MC
    Clin Cancer Res; 2004 Feb; 10(4):1446-53. PubMed ID: 14977848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combretastatin A4/poly(
    Ou Y; Tang ZH; Sun L; Yu HY; Li J; Zhao MH; Xu H
    Asian J Pharm Sci; 2018 Mar; 13(2):191-196. PubMed ID: 32104392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A poly(l-glutamic acid)-combretastatin A4 conjugate for solid tumor therapy: Markedly improved therapeutic efficiency through its low tissue penetration in solid tumor.
    Liu T; Zhang D; Song W; Tang Z; Zhu J; Ma Z; Wang X; Chen X; Tong T
    Acta Biomater; 2017 Apr; 53():179-189. PubMed ID: 28167300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review of Cytotoxic CA4 Analogues that Do Not Target Microtubules: Implications for CA4 Development.
    Tarade D; Pandey S; McNulty J
    Mini Rev Med Chem; 2017; 17(16):1507-1514. PubMed ID: 27156516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanoparticles Composed of PEGylated Alternating Copolymer-Combretastatin A4 Conjugate for Cancer Therapy.
    Zhang Y; Liu X; Wang X; He P; Xiao C; Yu H; Chen X
    Macromol Biosci; 2021 Aug; 21(8):e2100077. PubMed ID: 34031970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anticancer drug released from near IR-activated prodrug overcomes spatiotemporal limits of singlet oxygen.
    Rajaputra P; Bio M; Nkepang G; Thapa P; Woo S; You Y
    Bioorg Med Chem; 2016 Apr; 24(7):1540-9. PubMed ID: 26928287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and characterization of a photoresponsive doxorubicin/combretastatin A4 hybrid prodrug.
    Liu W; Liang L; Zhao L; Tan H; Wu J; Qin Q; Gou X; Sun X
    Bioorg Med Chem Lett; 2019 Feb; 29(3):487-490. PubMed ID: 30553736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Covalent functionalization of SWCNT with combretastatin A4 for cancer therapy.
    Assali M; Zaid AN; Kittana N; Hamad D; Amer J
    Nanotechnology; 2018 Jun; 29(24):245101. PubMed ID: 29583132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis, in vitro, and in vivo evaluation of phosphate ester derivatives of combretastatin A-4.
    Hadimani MB; Hua J; Jonklaas MD; Kessler RJ; Sheng Y; Olivares A; Tanpure RP; Weiser A; Zhang J; Edvardsen K; Kane RR; Pinney KG
    Bioorg Med Chem Lett; 2003 May; 13(9):1505-8. PubMed ID: 12699742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Folate receptor-mediated enhanced and specific delivery of far-red light-activatable prodrugs of combretastatin A-4 to FR-positive tumor.
    Nkepang G; Bio M; Rajaputra P; Awuah SG; You Y
    Bioconjug Chem; 2014 Dec; 25(12):2175-88. PubMed ID: 25351441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deciphering the origins of molecular toxicity of combretastatin A4 and its glycoconjugates: interactions with major drug transporters and their safety profiles
    Huang Z; Li G; Wang X; Xu H; Zhang Y; Gao Q
    Medchemcomm; 2017 Jul; 8(7):1542-1552. PubMed ID: 30108866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PI3Kgamma Inhibitor Attenuates Immunosuppressive Effect of Poly(l-Glutamic Acid)-Combretastatin A4 Conjugate in Metastatic Breast Cancer.
    Qin H; Yu H; Sheng J; Zhang D; Shen N; Liu L; Tang Z; Chen X
    Adv Sci (Weinh); 2019 Jun; 6(12):1900327. PubMed ID: 31380170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combretastatin A4-induced differential cytotoxicity and reduced metastatic ability by inhibition of AKT function in human gastric cancer cells.
    Lin HL; Chiou SH; Wu CW; Lin WB; Chen LH; Yang YP; Tsai ML; Uen YH; Liou JP; Chi CW
    J Pharmacol Exp Ther; 2007 Oct; 323(1):365-73. PubMed ID: 17646428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Site-specific and far-red-light-activatable prodrug of combretastatin A-4 using photo-unclick chemistry.
    Bio M; Rajaputra P; Nkepang G; Awuah SG; Hossion AM; You Y
    J Med Chem; 2013 May; 56(10):3936-42. PubMed ID: 23631389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structurally simplified biphenyl combretastatin A4 derivatives retain in vitro anti-cancer activity dependent on mitotic arrest.
    Tarade D; Ma D; Pignanelli C; Mansour F; Simard D; van den Berg S; Gauld J; McNulty J; Pandey S
    PLoS One; 2017; 12(3):e0171806. PubMed ID: 28253265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis, antiproliferative, anti-tubulin activity, and docking study of new 1,2,4-triazoles as potential combretastatin analogues.
    Mustafa M; Abdelhamid D; Abdelhafez EMN; Ibrahim MAA; Gamal-Eldeen AM; Aly OM
    Eur J Med Chem; 2017 Dec; 141():293-305. PubMed ID: 29031074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Liposome formulations of combretastatin A4 and 4-arylcoumarin analog prodrugs: antitumor effect in the mouse model of breast cancer].
    Mouseeva EV; Kuznetsova NR; Svirshchevskaia EV; Bovin NV; Sitnikov NC; Shavyrin AS; Beletskaia IP; Combes S; Fedorov AIu; Vodovozova EL
    Biomed Khim; 2012; 58(3):326-38. PubMed ID: 22856138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Co-administration of combretastatin A4 nanoparticles and sorafenib for systemic therapy of hepatocellular carcinoma.
    Wang Y; Yu H; Zhang D; Wang G; Song W; Liu Y; Ma S; Tang Z; Liu Z; Sakurai K; Chen X
    Acta Biomater; 2019 Jul; 92():229-240. PubMed ID: 31100462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.